Neurotechnology
Neuralink
Elon Musk's brain-computer interface company implanting its N1 device via the R1 surgical robot, running the PRIME trial (quadriplegia/ALS patients controlling computers and robotic arms via thought) and the VOICE trial (decoding speech from thought). Neuralink reached its 26th human trial participant in 2026, up from 21 in January, after expanding trials to the UAE, UK and Canada, and raised a $650 million Series E in April 2026 at a roughly $9 billion valuation, bringing total funding to about $1.85 billion since founding.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
3 sources · 59% avg. source confidence
- Basenor / MobiHealthNews — Neuralink reaches 26th patient in ongoing brain-computer interface trials62% source confidence
- Sacra / Tracxn — Neuralink raises $650M Series E at ~$9B valuation58% source confidence
- Interesting Engineering / Fierce Biotech — Neuralink advances Blindsight vision implant, hires former FDA executive56% source confidence
Dependency Map
What Neuralink depends on below, and who depends on Neuralink above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Bloomberg reported secondary-market share sales implying an $8.5 billion valuation
40% confidenceBloomberg reported that Neuralink insider share sales on secondary markets implied a valuation near $8.5 billion, ahead of the company's confirmed $9 billion pre-money Series E — with some later secondary trades reportedly implying materially higher figures.
Reported by Bloomberg News; secondary-market pricing is not an official company valuation and can diverge significantly from primary round terms.
Neuralink's Timeline
A sourced, dated history of Neuralink's key moments — founding to present.
Jan 2026 · Blindsight vision-restoration implant begins first patient trial
Neuralink's Blindsight implant, aimed at restoring vision for people who are completely blind, is scheduled for its first patient trial in 2026, expanding the company's clinical scope beyond motor and speech applications.
Jan 2026 · First Canadian ALS patient implanted; targets high-volume production
Neuralink implanted its first Canadian patient (an ALS patient) under the four-year CAN-PRIME clinical trial at UHN Toronto Western Hospital, evaluating the N1 implant and R1 surgical robot for Canadian residents with cervical spinal cord injury or ALS; separately, Elon Musk announced plans to begin high-volume production of Neuralink's brain-computer interface devices in 2026 alongside a shift toward an almost entirely automated surgical implantation procedure.
Apr 2026 · $650M Series E at ~$9B valuation
Neuralink raised a $650 million Series E round in April 2026 at a roughly $9 billion valuation, bringing total funding to approximately $1.85 billion since founding.